Disrupting Dengue with an Emerging Markets Launch Strategy Case Solution
The business invested 20 years and also invested $1.7 billion to establish Dengvaxia, taking numerous high-risk choices and making compromises along the way. The scenario feature the stakeholder interdependencies and also unpredictabilities that stayed as the vaccine execution program sneaked more detailed. It might possibly provide a plan for various other if effectively solved.
Sanofi Pasteur's freshly authorized dengue vaccine, Dengvaxia, was uncommon because it was introduced in the Philippines and various other at-risk nations. By opting to "turn the design" - launch in a developing market setting rather than industrialized markets - it needed to conquer different challenges throughout the worth chain, from enrollment to funding to provide.
PUBLICATION DATE: September 26, 2016
This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE
Related Case Solutions & Analyses:
IBM Values and Corporate Citizenship
Cancer Treatment Centers of America (B)
The Leadership Disease…and its Potential Cures
Prime Time: The Strategic use of Subconscious Priming to Enhance Customer Satisfaction
China Vanke (A-3)
Magnolia Community Initiative: A Network Approach to Population-Level Change
Nestle: Agricultural Material Sourcing Within the Concept of Creating Shared Value (CSV)
Embracing Openness: Designing for the Loss of Control
Improving Customer Service in Sunpharma Pharmacies
Opening Up The Boundaries of the Firm
